6-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Envision Healthcare Corporation and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif., Sept. 27, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE:EVHC). Investors who purchased or otherwise acquired Envision shares from March 2, 2015 through July 21, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the October 3, 2017 lead plaintiff motion deadline.

If you purchased shares of Envision during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Envision made materially false and/or misleading statements, and/or failed to disclose material information, to investors. On July 24, 2017, The New York Times reported that hospitals associated with the Company’s subsidiary, EmCare Holdings, Inc., were disproportionately likely to engage in “surprise billing,” in which patients who sought treatment at in-network facilities were treated by out-of-network physicians and then billed at higher rates. Following this news, Envision’s stock price fell materially, which harmed investors according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]